This site is intended only for all Healthcare Professionals residing in South Africa
Menu
Close
Menu
Close
The most common serious adverse reactions were serious infections. The most common serious infections reported with XELJANZ® (tofacitinib) were pneumonia, cellulitis, herpes zoster, urinary tract infection, diverticulitis, and appendicitis. Among opportunistic infections, TB and other mycobacterial infections, cryptococcus, histoplasmosis, oesophageal candidiasis, multidermatomal herpes zoster, cytomegalovirus, BK virus infections and listeriosis were reported with XELJANZ® (tofacitinib). Some patients have presented with disseminated rather than localised disease. Other serious infections that were not reported in clinical studies may also occur (e.g., coccidioidomycosis).1
The most commonly reported adverse reactions during the first 3 months in controlled clinical trials were headache, upper respiratory tract infections, nasopharyngitis, diarrhoea, nausea and hypertension.
The proportion of patients who discontinued treatment due to adverse reactions during first 3 months of the double-blind, placebo or MTX controlled studies was 3.8 % for patients taking XELJANZ® (tofacitinib). The most common infections resulting in discontinuation of therapy were herpes zoster and pneumonia.1
The ADRs listed in the table below are from clinical studies in patients with RA, PsA, and UC and are presented by System Organ Class (SOC) and frequency categories, defined using the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000), very rare (< 1/10 000), or not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.1
Copyright ©2024 Pfizer South Africa All rights reserved.
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for all Healthcare Professionals residing in South Africa. If you are a member of the public wishing to access information on a specific medicine, please visit www.pfizer.co.za.
This website is brought to you by Pfizer South Africa
Pfizer Laboratories (Pty) Ltd. Company Reg. No. 1954/000781/07. Building 2, 1st Floor, Maxwell Office Park, Magwa Crescent, Waterfall City, Midrand, Johannesburg, South Africa. Tel. No: 0860 PFIZER (734937).
Copyright © 2024. Pfizer Laboratories (Pty) Ltd. All rights reserved
These pages are not intended for patients or for members of the general public. The healthcare professional webpages contain promotional content.
I confirm that I am a healthcare professional residing in South Africa. If you select 'No', you will be redirected to Pfizer.co.za where you will be able to access reference information on Pfizer's prescription medicines.